Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 14/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 13/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 13/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 13/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.47 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146194 | 1.00 | CHRNA7 (0.48) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1146192 | 0.90 | CHRNA7 (0.48) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1146195 | 0.90 | CHRNA7 (0.48) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1146047 | 0.87 | CHRNA7 (0.48) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1146048 | 0.87 | CHRNA7 (0.48) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3840554 | 0.87 | CHRNA7 (0.63) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3840552 | 0.87 | CHRNA7 (0.63) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1145766 | 0.87 | CHRNA7 (0.46) | CHRNA7NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1145763 | 0.87 | CHRNA7 (0.46) | CHRNA7NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1146295 | 0.87 | CHRNA7 (0.48) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475811-B2 | 1-aza-bicyclo[3.3.1]nonanes | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20150087650-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| US-8933090-B2 | 1-aza-bicyclo[3.3.1]nonanes | NOVARTIS AG (CH) | 2015-01-13 | — | — | US | disclosed |
| EP-2336129-A1 | 1-aza-bicyclo[3.3.1]nonanes | Novartis AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-20110034475-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG | 2011-02-10 | — | — | US | disclosed |
| US-20070249657-A1 | 1-Aza-Bicyclo3.3.1Nonanes | NOVARTIS AG (CH) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249657-A1 | 1-Aza-Bicyclo3.3.1Nonanes | CBR3, CBR1, HCAR3 | CHRNA7 119/4885CHRNB2 710/4885CHRNB4 175/4885 |
| US-20110034475-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | CBR3, CBR1, HRH4 | CHRNA7 208/4885CHRNB2 845/4885CHRNB4 195/4885 |
| US-20150087650-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | CBR3, CBR1, ADCY3 | CHRNA7 228/4885CHRNB2 992/4885CHRNB4 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.